What is osteosarcoma?
About
“About 2% of childhood cancers are osteosarcomas.”
“Each year, approximately 1,000 new cases of osteosarcoma are diagnosed in the United States. About half of these cases are in children and teens.”
“Most osteosarcomas occur in children, teens, and young adults between the ages of 10 and 30. Teens are the most commonly affected age group, but people of any age can develop osteosarcoma.”
A Rare, Aggressive Pediatric Cancer
Osteosarcoma is the most common type of bone cancer, predominantly affecting children, teenagers, and young adults. This aggressive cancer typically originates in the long bones of the arms and legs, though it can occur in any bone in the body. Despite being a relatively rare disease, osteosarcoma is particularly devastating due to its aggressive nature, the complexity of treatment, and its significant impact on children and teens.
The challenge: A Tough Battle
Osteosarcoma presents a formidable challenge in the medical field. The treatment protocol has not changed in 42 years and usually involves a combination of surgery, chemotherapy, and sometimes radiation. While these methods can be effective, they often come with severe side effects and long-term consequences, including limb amputation and a high risk of recurrence. Furthermore, the survival rate for osteosarcoma has remained relatively stagnant over the past several decades, highlighting the urgent need for more effective therapies.
“86.9% of osteosarcoma survivors experience at least one chronic medical condition, and over 50% experience two or more conditions.”
“The 5-year relative survival rate for osteosarcoma is 59%. The 5-year relative survival rate for osteosarcoma that has metastasized to the lung is 24%.”
“In approximately 15% to 20% of patients, osteosarcoma has spread by the time it is diagnosed.”
Why your support matters
Research is the key to unlocking better treatments and ultimately a cure for osteosarcoma. And research requires funding. Advancements in understanding the molecular and genetic underpinnings of this cancer have opened up new avenues for targeted therapies. These therapies aim to attack the cancer cells more precisely, sparing healthy tissue and reducing the harsh side effects associated with traditional treatments.
However, research funding for osteosarcoma is limited, largely due to its relative rarity. This is where donors can make a profound difference. By supporting osteosarcoma research, donors can help accelerate the development of new treatments, support clinical trials, and bring hope to patients and their families.